LidexaGel 5%
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- LidexaGel 5%
- Generic name
- LIDOCAINE HCL
- Manufacturer
- Oncora Pharma, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- b45a7d2f-111f-4390-9b90-570b1c9f5ffc
- SPL ID
- 3899614e-a1ed-4642-937b-5d8e55a81c9a
- Version
- 1
- Effective date
- 2026-07-08
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:14:32
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | LidexaGel 5% | openfda.brand_name | |
| generic name | LIDOCAINE HCL | openfda.generic_name | |
| manufacturer name | Oncora Pharma, LLC | openfda.manufacturer_name | |
| ndc | package | 85477-730-07 | openfda.package_ndc |
| ndc | product | 85477-730 | openfda.product_ndc |
| ndc11 | package | 85477073007 | derived:openfda.package_ndc |
| rxcui | 1010057 | openfda.rxcui | |
| spl id | 3899614e-a1ed-4642-937b-5d8e55a81c9a | id | |
| spl set id | b45a7d2f-111f-4390-9b90-570b1c9f5ffc | set_id | |
| unii | V13007Z41A | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS: For external use only. Not for ophthalmic use.
warnings and cautions
PRECAUTIONS: If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. LidavexGel 5% should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.